GlaxoSmithKline_NN
73_CD
Financial_NN
statements_NOMZ
This_DEMO
section_NOMZ
comprises_VPRT
the_DT
Directors_NN
statements_NOMZ
,_,
the_DT
independent_JJ
auditors_NN
report_VPRT [PUBV]
on_PIN
the_DT
Financial_NN
statements_NOMZ
,_,
the_DT
Financial_NN
statements_NOMZ
consisting_VBG [WZPRES]
of_PIN
the_DT
principal_JJ
Financial_NN
statements_NOMZ
and_CC
supporting_VBG
notes_NN
,_,
and_ANDC
additional_JJ
financial_JJ
data_NN
._.
74_CD
Directors_NN
statements_NOMZ
of_PIN
responsibility_NOMZ
75_CD
Independent_NN
Auditors_NN
report_VPRT [PUBV]
Financial_JJ
statements_NOMZ
76_CD
Consolidated_NN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
76_CD
Consolidated_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
78_CD
Consolidated_NN
statement_NOMZ
of_PIN
cash_NN
ow_NN
80_CD
Consolidated_NN
balance_NN
sheet_NN
80_CD
Reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
equity_NOMZ
shareholders_NN
funds_NN
81_CD
Company_NN
balance_NN
sheet_NN
82_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
1_CD
._.
New_NN
accounting_GER
policies_NN
and_PHC
requirements_NOMZ
4_LS
._.
Merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
6_CD
._.
Merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_CC
divested_JJ
businesses_NOMZ
8_CD
._.
Joint_NN
ventures_NN
and_CC
associated_VBN
undertakings_GER
11_CD
._.
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
24_CD
._.
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
account_NN
28_CD
._.
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
33_CD
._.
GlaxoSmithKline_NN
plc_NN
investment_NOMZ
in_PIN
subsidiary_NN
companies_NN
37_CD
._.
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
38_CD
._.
Principal_NN
Group_NN
companies_NN
Financial_NN
record_NN
142_CD
Quarterly_JJ
trend_NN
148_CD
Five_CD
year_NN
record_NN
